Literature DB >> 32039490

NAFLD-Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse.

Jose D Debes1,2, Andre Boonstra2, Robert J de Knegt2.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32039490      PMCID： PMC7135940          DOI： 10.1002/hep.31170

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  10 in total

Review 1.  The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.

Authors:  Cristina Margini; Jean F Dufour
Journal:  Liver Int       Date:  2015-12-25       Impact factor: 5.828

2.  The Way to the Liver Is Through the Pituitary Gland.

Authors:  Ashraf A Ashhab; Jeffrey Albrecht; Jose D Debes
Journal:  Am J Gastroenterol       Date:  2018-01       Impact factor: 10.864

3.  Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.

Authors:  Bonnie Bengtsson; Per Stål; Staffan Wahlin; Niklas K Björkström; Hannes Hagström
Journal:  Liver Int       Date:  2019-03-29       Impact factor: 5.828

Review 4.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Authors:  Zobair Younossi; Frank Tacke; Marco Arrese; Barjesh Chander Sharma; Ibrahim Mostafa; Elisabetta Bugianesi; Vincent Wai-Sun Wong; Yusuf Yilmaz; Jacob George; Jiangao Fan; Miriam B Vos
Journal:  Hepatology       Date:  2019-06       Impact factor: 17.425

5.  Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease.

Authors:  Ju Dong Yang; Fowsiyo Ahmed; Kristin C Mara; Benyam D Addissie; Alina M Allen; Gregory J Gores; Lewis R Roberts
Journal:  Hepatology       Date:  2019-10-21       Impact factor: 17.425

6.  Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017.

Authors:  Donghee Kim; Adeyinka C Adejumo; Eric R Yoo; Umair Iqbal; Andrew A Li; Edward A Pham; George Cholankeril; Jeffrey S Glenn; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2019-06-25       Impact factor: 22.682

7.  Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes.

Authors:  Karl Björkström; Stefan Franzén; Björn Eliasson; Mervete Miftaraj; Soffia Gudbjörnsdottir; Ylva Trolle-Lagerros; Ann-Marie Svensson; Hannes Hagström
Journal:  Clin Gastroenterol Hepatol       Date:  2019-04-19       Impact factor: 11.382

Review 8.  Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice.

Authors:  Amit G Singal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-15       Impact factor: 11.382

9.  Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma.

Authors:  Hashem B El-Serag; Thomas Tran; James E Everhart
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

10.  Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells.

Authors:  Neeraj K Saxena; Dipali Sharma; Xiaokun Ding; Songbai Lin; Fabio Marra; Didier Merlin; Frank A Anania
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701
  10 in total
  3 in total

1.  Hepatocellular carcinoma in primary sclerosing cholangitis and primary biliary cholangitis: a clinical and pathological study in an uncommon but emerging setting.

Authors:  Dustin E Bosch; Yoh Zen; Sarag A Boukhar; Yongjun Liu; Lin Cheng; Matthew M Yeh
Journal:  Virchows Arch       Date:  2021-08-20       Impact factor: 4.064

2.  The cross-talk between DDR1 and STAT3 promotes the development of hepatocellular carcinoma.

Authors:  Ye Lin; Haosheng Jin; Xianqiu Wu; Zhixiang Jian; Xiongfeng Zou; Jianfeng Huang; Renguo Guan; Xiangling Wei
Journal:  Aging (Albany NY)       Date:  2020-07-27       Impact factor: 5.682

3.  MicroRNA-506-3p targets SIRT1 and suppresses AMPK pathway activation to promote hepatic steatosis.

Authors:  Liang-Kai Hu; Jian-Qing Chen; Hao Zheng; Yuan-Ping Tao; Yuan Yang; Xuan-Fu Xu
Journal:  Exp Ther Med       Date:  2021-10-11       Impact factor: 2.447
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.